AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Which rewards card is better for travel? Explore options to maximize your travel benefits and choose the right card for you.
22,786 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Revolution Medicines has surged in 2026, with revolution medicines nearly 140% year-to-date gains drawing investor at...
July 2026 brings a fresh wave of opportunities in semiconductors. This guide reveals five names with durable demand, ...
Is crypto a solid investment in 2026? This guide weighs potential gains against volatility, regulatory shifts, and ri...
C3.AI reports two consecutive quarterly revenue declines, forcing investors to reassess its enterprise AI strategy as...
What could drive Entravision's 2025 earnings, and what should investors watch next? This guide breaks down the driver...
Switzerland tightens regulation and traders seek safer, cost-effective access to the forex market. This report highli...
When a founder-led brand hits a leadership cliff, markets react fast. This article explains why holding's stock crash...
Regulatory pressure around UnitedHealth shifts attention to two defensible, cash-generating stocks with strong divide...
FuelCell Energy leads a hydrogen stock rebound with a 15% jump as investors chase AI data center exposure. Bloom Ener...
An $18 million wager on a rental business with decades of dividend growth sounds ambitious. This article breaks down ...
Small AI plays can jump from obscurity to headlines fast. This guide analyzes the risks and potential rewards, with p...